"TGen is critical not only to our ability to find cures to cancer and other diseases, but also to diversifying Arizona's economy and helping our state attract high-wage, cutting-edge, bioscience jobs. I am pleased that my office helped bring the parties together to secure TGen's future in Arizona," said Attorney General Terry Goddard.
VARI is the research arm of the Van Andel Institute (VAI), established in 1996 as a philanthropic research and educational organization by the late Jay and Betty Van Andel. There are over 250 scientists and staff in 18 laboratories who study the genetic, cellular and molecular origins of cancer, Parkinson's and other diseases. VARI recently opened a 240,000 square-foot building expansion in downtown Grand Rapids, which will allow it to broaden its efforts to include additional neurological disorders and chronic illnesses.
"This agreement provides TGen and VARI a research platform from which to tackle many of today's leading diseases with greater strength of resources, and as important, redefines collaboration in a way that should enhance the biomedical sectors and provide economic benefit to both Arizona and Michigan," said David Van Andel, VARI Chairman and CEO.
The TGen-VARI alliance already has yielded significant benefits for Arizona by helping TGen secure a number of grants from the National Institutes of Health (NIH) under the American Recovery and Reinvestment Act (ARRA). TGen's 12 ARRA grants total $18.9 million. Based on U.S. Department of Commerce economic models, TGen's economic-stimulus funding could result in as much as $41.9 million in new business activity.
The economic impact includes projects at TGen's headquarters in Phoenix, its operations in Scottsdale and Flagstaff, its partners at Arizona State Universit
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute